CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer

NCT01191697 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Cancer
Gastric Cancer

Interventions

DRUG: bevacizumab
DRUG: trastuzumab
DRUG: oxaliplatin
DRUG: capecitabine

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]
[object Object]